Reflex Molecular Testing in Melanoma Diagnosis: When Should BRAF Mutation Testing Be Ordered and Who Should Order It?

Abstract

Keywords

targeted therapy reflex testing MAPK pathway metastatic melanoma advanced melanoma stage II

Get full access to this article

View all access options for this article.

References

Ghazawi

FM.

Lagacé

et al. Incidence, mortality, and spatiotemporal distribution of cutaneous malignant melanoma cases across Canada. J Cutan Med Surg. 2019;23(4):394-412.doi:10.1177/1203475419852048

31132871

Tarhini

Kudchadkar

. Predictive and on-treatment monitoring biomarkers in advanced melanoma: moving toward personalized medicine. Cancer Treat Rev. 2018;71:8-18.doi:10.1016/j.ctrv.2018.09.005

30273812

Zhou

Sikorski

et al. Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Cancers. 2021;13(9):2282. doi:10.3390/cancers13092282

34068774

Cheema

PK.

Raphael

El-Maraghi

et al. Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists. Curr Oncol. 2017;24(1):16-22.doi:10.3747/co.24.3266

28270720

Miller

Walker

Shui

Brandtmüller

Cadwell

Scherrer

. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review. Melanoma Manag. 2020;7(1):MMT39.doi:10.2217/mmt-2019-0022

32399177